MedTrace Logo

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-02-17

No results posted yet for this study

Summary

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.

Conditions

  • Prostatic Neoplasms, Castration-Resistant
  • Neoplasms by Histologic Type
  • Neoplasms, Prostate
  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Neoplasms
  • Prostatic Neoplasms
  • Genital Neoplasms, Male
  • Urogenital Neoplasms
  • Neoplasms by Site
  • Prostatic Disease
  • Salivary Gland Cancer
  • Salivary Gland Tumor
  • Adenoid Cystic Carcinoma
  • Salivary Duct Carcinoma
  • Mucoepidermoid Carcinoma
  • Acinic Cell Tumor

Interventions

BIOLOGICAL

P-PSMA-101 CAR-T cells

P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).

DRUG

Rimiducid

Rimiducid (safety switch activator) may be administered as indicated

Sponsors & Collaborators

  • Poseida Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Rajesh Belani, M.D. · Sponsor Executive Medical Director

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2024-09-30
Completion
2024-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04249947 on ClinicalTrials.gov